Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2023-06-09 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
第六届监事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kangzhi Pharmaceutical Co., Ltd. It details decisions made during the fifth meeting of the sixth Supervisory Board, including approval of stock incentive plans, verification of incentive recipients, termination of a stock issuance plan, and appointment of the 2023 audit firm. The document is a formal announcement of board meeting resolutions rather than a full report or financial statement. It does not contain financial data or detailed audit results, nor is it a call transcript or shareholder voting result. It is not an annual or interim report, nor a regulatory filing of a different nature. The content fits best under Board/Management Information (MANG) as it relates to supervisory board decisions and management-level approvals.
2023-06-09 Chinese
2023年限制性股票激励计划激励对象名单
Remuneration Information Classification · 95% confidence The document is a detailed list of recipients of a restricted stock incentive plan for the year 2023, including allocation details and names of individuals involved. It is not a financial report, earnings release, or regulatory filing about financial results. It is also not an announcement of voting results or a proxy solicitation. The content focuses on the stock incentive plan allocation to management and core personnel, which is related to share-based compensation disclosures. Such disclosures typically fall under Remuneration Information filings, which detail compensation plans including stock incentives for executives and employees. The document is 3072 characters long, which is relatively short but contains substantive information about the incentive plan and recipients, not just an announcement or summary. Therefore, the best fitting category is Remuneration Information (DEF 14A).
2023-06-09 Chinese
关于参加2022年度海南辖区上市公司业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the company's participation in an investor performance explanation meeting for the 2022 fiscal year. It mentions that senior management will communicate with investors regarding the 2022 annual report, financial data, governance, and other topics. However, the document itself does not contain the annual report or detailed financial data; it is an announcement of an event related to discussing the annual report. The document length is short (599 characters), and it serves as a notice of participation in a performance explanation meeting rather than the report itself. Therefore, it fits best under Investor Presentation (IP) as it is about a presentation event for investors focusing on financials and company strategy.
2023-05-18 Chinese
关于举行2022年度网上业绩说明会的通知
AGM Information Classification · 95% confidence The document is a notice about holding an online performance explanation meeting for the 2022 annual report. It mentions that the 2022 annual report has already been published on April 24, 2023, and the meeting is scheduled for May 15, 2023. The document invites investors to participate and ask questions. The content is an announcement about an event related to the annual report, not the report itself. The document length is short (798 characters), and it does not contain financial data or detailed report content. Therefore, it fits the category of AGM Information (AGM-R), as it is about an annual general meeting-related presentation or event.
2023-05-09 Chinese
关于第一期员工持股计划存续期届满暨终止的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 康芝药业股份有限公司 regarding the expiration and termination of the first employee stock ownership plan. It details the history, management, and disposition arrangements of the employee stock plan, including dates, approvals, and dividend distributions. The document is a formal public announcement about the status and conclusion of an employee stock ownership plan, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather compliance and procedural information related to the employee stock plan. Given the content and length (3912 characters), it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-05-09 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '康芝药业股份有限公司2023 年第一季度报告' which translates to 'Kangzhi Pharmaceutical Co., Ltd. 2023 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial performance for the first quarter of 2023. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. There is no indication that this is an announcement of a report or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.